| __timestamp | Novavax, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 19928000 | 381287000 |
| Thursday, January 1, 2015 | 30842000 | 452612000 |
| Friday, January 1, 2016 | 46527000 | 316800000 |
| Sunday, January 1, 2017 | 34451000 | 330100000 |
| Monday, January 1, 2018 | 34409000 | 265800000 |
| Tuesday, January 1, 2019 | 34417000 | 336200000 |
| Wednesday, January 1, 2020 | 145290000 | 423900000 |
| Friday, January 1, 2021 | 298358000 | 467000000 |
| Saturday, January 1, 2022 | 488691000 | 487000000 |
| Sunday, January 1, 2023 | 468946000 | 477100000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Novavax, Inc. from 2014 to 2023. Over this period, United Therapeutics consistently maintained higher SG&A expenses, peaking in 2022 with nearly 487 million USD. In contrast, Novavax saw a dramatic increase, with expenses rising from approximately 20 million USD in 2014 to nearly 489 million USD in 2022, a staggering 24-fold increase. This surge reflects Novavax's aggressive expansion and investment in its operations, particularly during the COVID-19 pandemic. Meanwhile, United Therapeutics' expenses remained relatively stable, showcasing its strategic cost management. This comparison highlights the diverse strategies employed by biotech companies in navigating financial challenges and opportunities.
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Catalent, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Merus N.V.
Comparing SG&A Expenses: United Therapeutics Corporation vs Veracyte, Inc. Trends and Insights
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Incyte Corporation and Novavax, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Catalent, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights
Rhythm Pharmaceuticals, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?